In mice with therapy-resistant syngeneic tumors, we discovered that systemic administration of a specific small molecule GPER agonist (15) induces differentiation in tumor cells, inhibits their proliferation, and simultaneously renders the tumors more immunogenic. The gene discussed is GPER1; the disease is neoplasm.